InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,402.40
(
0.00%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.58
(
-0.38%
)
Bitcoin
65,645.45
(
-1.26%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: gdollasign post# 4944

Monday, 01/17/2011 3:19:25 PM

Monday, January 17, 2011 3:19:25 PM

Post# of 80490

Your comment is not only possible, it is probable.

Can it be that the original 2014 date was by design, just in case the primary endpoint was not met and the company wants to meet the secondary endpoint (OS) to have the drug approved.



When trials fail the primary and the company runs an open label extension to accumulate more data, that data will be exploratory and not be useful as registration data.

Ask DNDN.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up